Dulphy Nicolas, Chrétien Anne-Sophie, Khaznadar Zena, Fauriat Cyril, Nanbakhsh Arash, Caignard Anne, Chouaib Salem, Olive Daniel, Toubert Antoine
UMRS-1160, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France; U 1160, Université Paris Diderot, Sorbonne Paris Cité, Paris, France; Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Centre de Recherche en Cancérologie de Marseille (CRCM), Equipe Immunité et Cancer, INSERM, U1068, Institut Paoli-Calmettes, Aix-Marseille Université, UM 105, CNRS, UMR7258 , Marseille , France.
Front Immunol. 2016 Mar 9;7:94. doi: 10.3389/fimmu.2016.00094. eCollection 2016.
Acute myeloid leukemia (AML) is a heterogeneous group of malignancies which incidence increases with age. The disease affects the differentiation of hematopoietic stem or precursor cells in the bone marrow and can be related to abnormal cytogenetic and/or specific mutational patterns. AML blasts can be sensitive to natural killer (NK) cell antitumor response. However, NK cells are frequently defective in AML patients leading to tumor escape. NK cell defects affect not only the expression of the activating NK receptors, including the natural cytotoxicity receptors, the NK group 2, member D, and the DNAX accessory molecule-1, but also cytotoxicity and IFN-γ release. Such perturbations in NK cell physiology could be related to the adaptation of the AML to the immune pressure and more generally to patient's clinical features. Various mechanisms are potentially involved in the inhibition of NK-cell functions in AML, including defects in the normal lymphopoiesis, reduced expression of activating receptors through cell-to-cell contacts, and production of immunosuppressive soluble agents by leukemic blasts. Therefore, the continuous cross-talk between AML and NK cells participates to the leukemia immune escape and eventually to patient's relapse. Methods to restore or stimulate NK cells seem to be attractive strategies to treat patients once the complete remission is achieved. Moreover, our capacity in stimulating the NK cell functions could lead to the development of preemptive strategies to eliminate leukemia-initiating cells before the emergence of the disease in elderly individuals presenting preleukemic mutations in hematopoietic stem cells.
急性髓系白血病(AML)是一组异质性恶性肿瘤,其发病率随年龄增长而增加。该疾病影响骨髓中造血干细胞或前体细胞的分化,可能与异常的细胞遗传学和/或特定的突变模式有关。AML原始细胞对自然杀伤(NK)细胞抗肿瘤反应可能敏感。然而,NK细胞在AML患者中常常存在缺陷,导致肿瘤逃逸。NK细胞缺陷不仅影响激活型NK受体的表达,包括自然细胞毒性受体、NK细胞亚群2成员D和DNAX辅助分子-1,还影响细胞毒性和IFN-γ释放。NK细胞生理学的这种紊乱可能与AML对免疫压力的适应有关,更普遍地与患者的临床特征有关。AML中抑制NK细胞功能可能涉及多种机制,包括正常淋巴细胞生成的缺陷、通过细胞间接触导致激活受体表达降低以及白血病原始细胞产生免疫抑制性可溶性因子。因此,AML与NK细胞之间持续的相互作用参与了白血病的免疫逃逸,并最终导致患者复发。一旦实现完全缓解,恢复或刺激NK细胞的方法似乎是治疗患者的有吸引力的策略。此外,我们刺激NK细胞功能的能力可能会导致开发先发制人的策略,以在患有造血干细胞白血病前期突变的老年个体中疾病出现之前消除白血病起始细胞。